Haloperidol Decanoate Richter

Haloperidol Decanoate Richter is a prescription‑only intramuscular injection containing the butyrophenone antipsychotic haloperidol decanoate. Formulated as an oil suspension, it is marketed in the European Union for the long‑acting management of psychotic disorders. The product delivers haloperidol in a depot form, allowing sustained plasma concentrations after a single injection, which supports maintenance therapy in conditions such as schizophrenia and schizoaffective disorder and related mood disturbances.

Haloperidol Decanoate Richter is indicated for several psychiatric indications where long‑acting antipsychotic coverage is desired. The depot formulation provides steady drug levels for weeks after injection, facilitating stable symptom control. - Acute psychosis and severe agitation requiring rapid control. - Maintenance therapy for schizophrenia to reduce relapse risk. - Schizoaffective disorder when oral therapy is insufficient. - Adjunctive treatment in patients with poor adherence to daily oral antipsychotics. - Off‑label use in certain cases of bipolar disorder under specialist supervision.

Side effects of Haloperidol Decanoate Richter reflect its dopamine antagonism and can vary in frequency and severity.

Common: - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Sedation or drowsiness. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort. - Weight gain or metabolic changes.

Serious: - Neuroleptic malignant syndrome, a life‑threatening reaction. - Tardive dyskinesia with prolonged use. - Significant cardiac arrhythmias, including QT prolongation.

When prescribing Haloperidol Decanoate Richter, clinicians should evaluate patient history and monitor for specific safety concerns. - Assess for a history of cardiovascular disease or prolonged QT interval. - Use cautiously in patients with Parkinson’s disease or other movement disorders. - Monitor for signs of depression or suicidal thoughts, especially during early treatment. - Evaluate liver and renal function before initiating therapy. - Educate patients about the risk of orthostatic hypotension and falls. - Consider pregnancy and lactation status; use only if benefits outweigh risks.

Haloperidol Decanoate Richter may interact with several medications that affect its metabolism or cardiac safety profile.

Avoid: - Concurrent use with other dopamine antagonists or high‑potency antipsychotics. - Medications that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin.

Use with caution: - CYP3A4 inducers like rifampin, carbamazepine, or phenytoin, which may reduce haloperidol levels. - Central nervous system depressants, including benzodiazepines and opioids, which can increase sedation. - Anticholinergic agents that may mask extrapyramidal symptoms.